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Abstract
Introduction
Sepsis is an ongoing  cause of morbidity and mortality in the 
United States. It is the most common discharge diagnosis for adult 
patients and the costliest major cause of inpatient admissions 
(Esposito et al., 2018). The standard of care treatment involves 
early identification of infection, fluid resuscitation, and broad-
spectrum intravenous (IV) antibiotics until cultures can assist with 
narrowing to a specific pathogen (Rhodes et al., 2017). 
Unfortunately, in the time that it can take to identify the source of 
infection, many patients progress to septic shock, which carries a 
mortality rate of up to 80% (Paoli et al., 2018). Sepsis is loosely 
defined as a systemic infection that causes organ dysfunction due 
to the body’s immune response. Part of the dysregulation of the 
immune response involves inflammation, oxidative stress, and the 
body’s subsequent response. Given its antioxidant properties, the 
theoretical use of vitamin C supplementation in sepsis is not 
necessarily new, but is being studied more intensely in recent 
years, largely due to a promising 2016 retrospective study by Dr. 
Paul E. Marik of Norfolk, Virginia.
Research Questions
Literature Review
Applicability to Clinical 
Practice
Discussion
Due to the large incidence and society cost of sepsis and its 
sequelae, this has long been a major area of research. Several 
novel sepsis treatments have appeared promising and failed to 
produce meaningful results at the clinical trial level. Although 
the seemingly-dramatic outcomes have been met with 
skepticism by many, the current literature suggests that ascorbic 
acid may be the most promising new treatment for sepsis that 
clinicians have seen in a very long time. Its mechanism of 
action in the body serves many roles that are not only vital to 
the healthy individual, but physiologically suffering in cases of 
sepsis. As previously mentioned, there are several currently 
active clinical trials studying the use of intravenous ascorbic 
acid in treating patients with sepsis. Within the next few years, 
antioxidant therapy may become a viable treatment adjunct for 
patients with severe sepsis. At a minimum, if it shows enough 
benefit in early trials, the relatively low cost as well as lack of 
risk of adverse effects may allow it to be implemented as part of 
a sepsis protocol. In addition to larger sample sizes and blind, 
placebo-controlled trials, a specific dosing recommendation 
would need to be established, as well as at what point ascorbic 
acid would be administered during the timeline of the sepsis 
protocol.
Sepsis kills nearly 1 million people each year in the United 
States and sepsis-related hospitalizations cost approximately $24 
billion annually (Paoli, Reynolds, Sinha, Gitlin, & Crouser, 
2018). Current treatment guidelines are limited to targeted 
antibiotics and hemodynamic support. While antibiotics are the 
definitive treatment to eradicate the infectious pathogen, there 
are currently no standard-of-care treatments that consistently and 
successfully attenuate the damage sustained to the body by its 
own inflammatory response to infection. Many different 
treatments have been trialed and failed to show improved 
outcomes. Vitamin C, or ascorbic acid, has long been associated 
with supporting immune function, and has been studied in the 
past in various related capacities. More recently, a study initiated 
by Dr. Paul Marik has spurred much discussion and additional 
research regarding the potential use of ascorbic acid as an 
adjunctive treatment for sepsis patients. Research suggests that it 
may reduce damage by reducing oxidative stress, regulate the 
body’s immune response, and facilitating the production of 
endogenous vasopressin. Discussion will include the mechanism 
of action of ascorbic acid in the body, its potential role, efficacy, 
and safety in the treatment of sepsis, as well as additional 
treatment components. Also discussed is the cost in both dollars 
and mortality, of waiting to implement the widespread use of 
what appears in some studies to be a low-cost, low-risk, high-
reward treatment.
• What is the role of ascorbic acid in the human body and what 
theoretical mechanisms of action does it have in a patient with 
sepsis?
• In patients with sepsis, has administration of intravenous 
ascorbic acid been shown to decrease mortality rates when 
compared to current standard of care? 
• At what dose might there be increased benefit from ascorbic 
acid supplementation, and is that dose beyond the standard 
replacement from enteral or parenteral nutrition that is routinely 
administered to critically ill patients?
• In treatment of sepsis, is intravenous ascorbic acid a cost 
effective treatment when combined with the current regimen of 
intravenous fluid resuscitation and antibiotic therapy? What are 
the risks and benefits to delaying implementation of this 
treatment option?
Mechanism of action
Vitamin C (ascorbic acid) has been proven to play many major 
roles in the normal function of the human body. The antioxidant 
properties of ascorbic acid help to prevent oxidative stress from 
causing damage to cellular proteins. It also aids in the creation and 
function of similarly-acting components. It helps to produce 
catecholamines, cortisol, and vasopressin (Moscowitz et al., 2018). 
It is a vital part of growth and repair of tissues due to its role in 
collagen formation, which is utilized throughout the body in many 
areas, including tendons, ligaments, and vasculature. 
Safety and Efficacy
In a randomized, double-blind, placebo-controlled trial by Fowler 
et al., 2014, no patients were removed from the study due to 
adverse events after receiving low or high-dose IV ascorbic acid. 
Marik (2017) has been credited with bringing this treatment into 
the public eye most recently. His study evaluated outcomes of 94 
patients being treated for sepsis. The primary outcome evaluated 
was in-hospital survival. He used a combination of ascorbic acid, 
thiamine, and hydrocortisone to treat 47 patients and then 
retrospectively matched them to previous patients with similar 
conditions who had been treated using only traditional standard of 
care for sepsis. The results appear to be dramatic. 
As stated, there are several trials currently in various stages. 
There are several areas that will need to be addressed before 
widespread implementation can take place. While this research 
currently applies to critical care as opposed to primary care, 
significant benefit from use of high-dose ascorbic acid in 
infectious disease could translate to research its use in less 
severe illness. As more research becomes available, the use of 
parenteral ascorbic acid could be a life-saving and cost-effective 
treatment option for patients with severe sepsis. 
Statement of the Problem
The average inpatient length of stay for a patient with sepsis is 
75% longer than for other illnesses, requiring corresponding 
supplies and staffing. In 2013, only 3.6% of hospital stays were 
due to sepsis, but this population utilized 13% of the cost of 
resources at approximately $24 billion. (Paoli, et al., 2018) 
Oxidative stress on vasculature during acute sepsis can lead to 
hemodynamic instability, increased inflammation, and death. 
Patients who progress from sepsis to septic shock have mortality 
rates of approximately 30-50% (Carr, Shaw, Fowler, & Natarajan, 
2015). Aside from current antibiotics, there are no other mainstay 
medications in treatment of sepsis. 
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The treatment group saw only 4 fatalities, and no patients 
developed progressive organ failure. Carr et al., (2017) found 
that C-reactive protein levels were shown to be inversely 
related to that of serum vitamin C levels, and supplementation 
of vitamin C appeared to cause C-reactive protein levels to 
decrease. 
Benefits at low vs high doses
In Fowler et al, 2014, the patients who received the high-dose 
ascorbic acid (200mg/kg) saw a faster rate of improvement in 
terms of decreasing need for exogenous vasopressors and 
decreased need for mechanical ventilation when compared to 
patients who were given low-dose ascorbic acid (50mg/kg) or 
placebo.
Cost of delaying new treatments
Due to the fact that the treatment components themselves are 
relatively low cost, and the fact that thiamine and 
hydrocortisone, as well as ascorbic acid in smaller doses, are 
already often administered to critically-ill patients, and the 
lack of evidence demonstrating serious adverse effects from 
high-dose ascorbic acid, it seems reasonable in this case to 
consider early implementation of this adjunct sepsis 
treatment. The major flaw in this discussion is that since this 
treatment is not being widely used, the costs and patient 
outcomes were theoretical and based on an observational 
study with a small sample size. More specific cost estimates 
for the treatment as well as for training of staff could be 
useful to aid in decision-making (Blythe, Cook, & Graves, 
2018).
In the United States, nearly 1 million patients are 
admitted each year for sepsis. Many sources suggest that 
the incidence is increasing. One study reports an increase 
of 8.7% per year over the course of 20-years. More than 
half of all inpatient deaths are due to infection. In 
addition to the lives lost, sepsis draws a large amount of 
money and resources.
